Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Capital Expenditures: 2019-2025

Historic Capital Expenditures for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $302,000.

  • C4 Therapeutics' Capital Expenditures rose 2423.08% to $302,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $482,000, marking a year-over-year decrease of 48.78%. This contributed to the annual value of $180,000 for FY2024, which is 89.46% down from last year.
  • As of Q3 2025, C4 Therapeutics' Capital Expenditures stood at $302,000, which was up 7,650.00% from -$4,000 recorded in Q4 2024.
  • In the past 5 years, C4 Therapeutics' Capital Expenditures registered a high of $3.1 million during Q2 2022, and its lowest value of -$13,000 during Q3 2024.
  • Its 3-year average for Capital Expenditures is $273,750, with a median of $249,500 in 2024.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 102.55% in 2024, then surged by 2,423.08% in 2025.
  • C4 Therapeutics' Capital Expenditures (Quarterly) stood at $109,000 in 2021, then spiked by 1,266.97% to $1.5 million in 2022, then plummeted by 89.46% to $157,000 in 2023, then crashed by 102.55% to -$4,000 in 2024, then surged by 2,423.08% to $302,000 in 2025.
  • Its last three reported values are $302,000 in Q3 2025, -$4,000 for Q4 2024, and -$13,000 during Q3 2024.